KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Receivables (2016)

Novavax (NVAX) has 7 years of Change in Receivables data on record, last reported at -$356000.0 in Q4 2016.

  • For Q4 2016, Change in Receivables rose 82.31% year-over-year to -$356000.0; the TTM value through Dec 2016 reached -$2.1 million, up 75.56%, while the annual FY2021 figure was -$144.4 million, 41.25% up from the prior year.
  • Change in Receivables reached -$356000.0 in Q4 2016 per NVAX's latest filing, down from $236000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.8 million in Q4 2014 and bottomed at -$6.0 million in Q2 2015.
  • Average Change in Receivables over 5 years is -$361850.0, with a median of -$233500.0 recorded in 2012.
  • Peak YoY movement for Change in Receivables: surged 1661.25% in 2014, then tumbled 2569.23% in 2016.
  • A 5-year view of Change in Receivables shows it stood at -$1.5 million in 2012, then surged by 110.97% to $160000.0 in 2013, then soared by 1661.25% to $2.8 million in 2014, then crashed by 171.43% to -$2.0 million in 2015, then soared by 82.31% to -$356000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$356000.0 in Q4 2016, $236000.0 in Q3 2016, and -$26000.0 in Q2 2016.